Journal of exploratory research in pharmacology最新文献_第7页

Pre-clinical Exploratory Evaluation of Mab806-derived Immunotoxin in Targeting Solid Tumors with High Potency and Selectivity Towards EGFRvIII mab806衍生免疫毒素高效选择性靶向实体瘤EGFRvIII的临床前探索性评价

Journal of exploratory research in pharmacology Pub Date : 2022-03-11 DOI: 10.14218/jerp.2022.00005

Yan Zhang, Q. Qiu, Jing-feng Xu, Hong Yang, Bing Sun

引用次数: 0

Optimizing Ethanol Extraction of Rosemary Leaves and Their Biological Evaluations 迷迭香叶乙醇提取工艺优化及其生物学评价

Journal of exploratory research in pharmacology Pub Date : 2022-03-11 DOI: 10.14218/jerp.2022.00002

Walid Yeddes, Hammami Majdi, Hamza Gadhoumi, Taycir Grati Affes, S. N. Mohamed, W. Aidi Wannes, Moufida Saidani-Tounsi

引用次数: 1

Delivery System for Targeted Drug Therapy in Chronic Diseases 慢性疾病靶向药物治疗的递送系统

Journal of exploratory research in pharmacology Pub Date : 2022-03-08 DOI: 10.14218/jerp.2021.00052

Yuan-Qi Jiang, Jin-Peng Chen, Yu Dong, Fu-Jun Zhou, Cheng-Wang Tian, Chang-Qing Chen

引用次数: 1

Impact of COVID-19 on Patients with Inflammatory Bowel Disease. COVID-19 对炎症性肠病患者的影响

Journal of exploratory research in pharmacology Pub Date : 2022-03-01 Epub Date: 2021-10-12 DOI: 10.14218/jerp.2021.00014

Paula A Ambrose, Wendy A Goodman

{"title":"Impact of COVID-19 on Patients with Inflammatory Bowel Disease.","authors":"Paula A Ambrose, Wendy A Goodman","doi":"10.14218/jerp.2021.00014","DOIUrl":"10.14218/jerp.2021.00014","url":null,"abstract":"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan, China, in late 2019. Responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic, SARS-CoV-2 is one of three structurally similar beta-coronaviruses that can cause a strong upregulation of cytokines referred to as cytokine release syndrome (CRS). Unresolved CRS leads to respiratory symptoms, including pneumonia, and in more severe cases, acute respiratory distress syndrome (ARDS). Although COVID-19 is widely known for these hallmark respiratory symptoms, it also impacts the gut, causing gastrointestinal (GI) tract inflammation and diarrhea. COVID-19's GI symptoms may be due to the high intestinal expression of angiotensin converting enzyme-2 receptors, which are for the binding of SARS-CoV-2 viral particles. Reports have shown that SARS-CoV-2 can be passed through fecal matter, with one study finding that 48.1% of COVID-19 patients expressed viral SARS-CoV-2 mRNA in their stool. Given that the GI tract is a target tissue affected by COVID-19, this causes concern for those with underlying GI pathologies, such as inflammatory bowel disease (IBD). Regrettably, there have been only limited studies on the impact of COVID-19 on gut health, and the impact of COVID-19 on intestinal inflammation among IBD patients remains unclear. In particular, questions regarding susceptibility to SARS-CoV-2 infection, clinical impact of COVID-19 on IBD, and the potential influence of age, sex, and immunosuppressant medications are still poorly understood. An improved understanding of these issues is needed to address the unique risks of COVID-19 among IBD patients, as well as the potential impact of SARS-CoV-2 on the host intestinal microbiota.</p>","PeriodicalId":73746,"journal":{"name":"Journal of exploratory research in pharmacology","volume":"7 1","pages":"37-44"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b2/84/nihms-1774288.PMC9373928.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9375922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of NLRP3 Inflammasome-related Modulators in Sepsis NLRP3炎性小体相关调节剂在脓毒症中的应用

Journal of exploratory research in pharmacology Pub Date : 2022-02-18 DOI: 10.14218/jerp.2021.00055

Ming-he Yang, Chunlei Duan, Shanshou Liu, Jian-Gang Xie

引用次数: 0

Computational Drug Screening in COVID-19 Drug Repurposing Research: Encouraging Findings and Limitations COVID-19药物再利用研究中的计算药物筛选:令人鼓舞的发现和局限性

Journal of exploratory research in pharmacology Pub Date : 2022-02-10 DOI: 10.14218/jerp.2021.00061

Apostolos Zarros

引用次数: 0

Journal of exploratory research in pharmacology Pub Date : 2022-01-30 DOI: 10.14218/jerp.2021.00036

Xue-Shan Huang, Zheng Zhu, Xiao-ling Li, Hui Luo, Lianxiang Luo

引用次数: 1

Formulation and Characterization of Lacosamide-loaded Polymeric Microneedles lacosamide负载聚合物微针的制备与表征

Journal of exploratory research in pharmacology Pub Date : 2022-01-29 DOI: 10.14218/jerp.2021.00051

K. Aykaç, E. Başaran

{"title":"Formulation and Characterization of Lacosamide-loaded Polymeric Microneedles","authors":"K. Aykaç, E. Başaran","doi":"10.14218/jerp.2021.00051","DOIUrl":"https://doi.org/10.14218/jerp.2021.00051","url":null,"abstract":"Background and objectives: Epilepsy is a neural disorder that occurs because of a disruption in neural conduc-tions in various parts of the brain and is mainly characterized by seizures, pensive gaze, involuntary mimics, contractions, meaningless speeches, repetitive movements, and loss of consciousness. The serious side effects of conventional drug delivery systems due to high applied doses, low transition rates to the brain, and limitations of drug application during seizures result in the urgent need for novel drug delivery systems for the enhanced treatment of epilepsy. Methods: In this study, Lacosamide was selected because of its high therapeutic dose, which is due to its low transition to the target site. Microneedle patches were formulated by micromolding of polymers of carboxy-methyl cellulose (CMC) and Eudragit S 100 (ES100) for a unique route for applications to reduce the applied dose to minimize the severe side effects. This strategy enhanced brain transition via the nasal route and over-came the blood-brain barrier (BBB) to minimize the applied dose. Characterization studies were performed in detail. Results: The results revealed that the releases of Lacosamide extended to 96 h with ES100 microneedle patches. In contrast, CMC microneedles released almost all the active ingredients within 1 h due to the hydrophilic nature of the polymer. Stability studies indicated that the formulations were stable at 25 ± 2°C (60 ± 5% Relative Humid-ity; RH), 40 ± 2°C (75 ± 5% RH) and 5 ± 3°C for 6 months. Conclusions: By considering the film like structures, polymeric microneedle patches have the potential for Lacosa-mide delivery through the unconventional nasal route for the improved treatment of epilepsy.","PeriodicalId":73746,"journal":{"name":"Journal of exploratory research in pharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42856934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artemisia annua L. and Its Derivatives: Their Antiviral Effects on COVID-19 and Possible Mechanisms 黄花蒿及其衍生物对COVID-19的抗病毒作用及其可能机制

Journal of exploratory research in pharmacology Pub Date : 2022-01-24 DOI: 10.14218/jerp.2021.00034

I. Ahmad, Rahman Ali, Monyck Jeane dos Santos Lopes, C. H. Steinmetz, F. Haq

引用次数: 2

Identification of Bioactive Components in QingFeiPaiDu Decoction for Treatment of COVID-19 by Network Pharmacology 网络药理学鉴定清肺排毒汤治疗新型冠状病毒肺炎的生物活性成分

Journal of exploratory research in pharmacology Pub Date : 2022-01-20 DOI: 10.14218/jerp.2021.00044

Kwong‐Fai Wong

引用次数: 0